• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC

byDaniel GoldshteinandSze Wah Samuel Chan
January 13, 2025
in Chronic Disease, Oncology
Reading Time: 3 mins read
Dacomitinib may be effective in EGFR-associated lung cancer
Share on FacebookShare on TwitterShare on LinkedIn

1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant).

2. Grade 3-4 treatment-related adverse events were reported in 14% in the immunotherapy arm vs 36% in the chemotherapy arm.

Evidence Rating Level: 1 (Excellent)

Study Rundown: PD-L1 immune checkpoint inhibitor in combination with chemotherapy has expanded neoadjuvant treatment options for resectable non–small cell lung cancer (NSCLC). Some early research shows the potential of combining a PD-L1 inhibitor (nivolumab) with a CTLA-4 inhibitor (ipilimumab) in this population. This phase 3 trial further explored this immunotherapy couplet and compared it to standard chemotherapy in resectable NSCLC. The endpoints assessed included event-free survival (EFS), EFS with next line of treatment (EFS2), pathological complete response (pCR), major pathologic response (MPR), overall survival (OS), time to death or distant metastases (TTDM), and safety. Surgical rates were 73% in immunotherapy arm and 76% in chemotherapy arm. R0 resection was achieved in 80% and 71% of patients in the immunotherapy and chemotherapy arms, respectively. The median follow-up time was 49.2 months. Median EFS was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant), and 3-year EFS rates were 56% and 44%, respectively. EFS2 HR 0.70 (non-significant). Among the PD-L1 <1% subgroup, EFS and surgical rates seemed to favour chemotherapy, although the sample size in this subgroup was small. The pCR rate was 20.4% in the immunotherapy arm vs 4.6% in the chemotherapy arm with OR 5.14 (significant), and MPR rates being 28.3% versus 14.8%, respectively. Recurrence rates after definitive surgery in the immunotherapy and chemotherapy arms were 23% and 44%, respectively, with TTDM HR 0.61 (significant). OS data was immature at the time of analysis, the median OS was not reached but the HR was 0.73 (non-significant), and 3-year OS rates were 73% vs 61%, respectively. For safety, grade 3-4 treatment-related adverse events were reported in 14% in the immunotherapy arm vs 36% in the chemotherapy arm, with the most common grade 3-4 immune-related adverse event was diarrhea/colitis (3%). The strengths of this study included its methodology, and the limitations included the small sample size. Overall, this study found doublet immunotherapy improves some endpoints and has a lower rate of high-grade toxicity when compared to doublet chemotherapy in resectable NSCLC.

Click to read the study in the JCO (Journal of Clinical Oncology)

Relevant Reading: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

RELATED REPORTS

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in final phase 3 results

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

FDA approvedFor NSCLC: Jideytro (zidesamtinib), Jul 22, 2026→

In-Depth [randomized controlled trial]: This open-label, international phase 3 trial enrolled adults with newly diagnosed stage IB-IIIA NSCLC with no known mutations and randomized them (1:1) to neoadjuvant treatment with either nivolumab/ipilimumab (3/1, n=113) vs platinum-doublet chemotherapy (n=108). Surgery was planned for 6 weeks after the last neoadjuvant treatment and patients were eligible for optional adjuvant therapy with chemotherapy and/or radiotherapy per the investigator’s discretion (34% in the immunotherapy arm and 32% in the chemotherapy arm). Surgical rates were 73% in the immunotherapy arm and 76% in the chemotherapy arm and reasons for surgery cancellation included disease progression (16% vs 8%), adverse events (3% vs 0%), and other reasons (7% vs 11%). R0 resection was achieved in 80% and 71% of patients in the immunotherapy and chemotherapy arms, respectively. The median follow-up time was 49.2 months (37.1-65.2). Median EFS was 54.8 months (95%CI, 24.4-not reached (NR)) with immunotherapy vs 20.9 months (14.2-NR) with chemotherapy, with HR 0.77 (95%CI, 0.51-1.15), and 3-year EFS rates were 56% and 44%, respectively. EFS2 HR 0.70 (95%CI, 0.45-1.08). Among the PD-L1 <1% subgroup, EFS and surgical rates seemed to favour chemotherapy, although the sample size in this subgroup was small. The pCR rate was 20.4% (95%CI, 13.4-29.0) in the immunotherapy arm vs 4.6% (95%CI, 1.5-10.5) in the chemotherapy arm with OR 5.14 (95%CI, 1.91-13.80), and MPR rates being 28.3% versus 14.8%, respectively. With respect to safety, grade 3-4 treatment-related adverse events were reported in 14% in the immunotherapy arm vs 36% in the chemotherapy arm, with the most common grade 3-4 immune-related adverse event was diarrhea/colitis (3%). Overall this study found doublet immunotherapy improves some endpoints and has a lower rate of high-grade toxicity when compared to doublet chemotherapy in resectable NSCLC.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chemotherapyimmunotherapynsclc
Previous Post

#VisualAbstract: Levofloxacin Does Not Significantly Reduce Incidence of Multidrug-Resistant Tuberculosis in Vietnam

Next Post

Postdischarge contacts may not significantly affect unplanned healthcare utilization or patient satisfaction

RelatedReports

Illustration showing the lungs with a tumor, a vial representing medication, and surgical tools, indicating lung cancer treatment involving toripalimab.
2MM Trial Briefs

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in final phase 3 results

October 26, 2026
A collage illustrating the urinary bladder, immune system elements, cancer cells, and an IV bag, highlighting immunotherapy for urothelial cancer.
Chronic Disease

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

September 22, 2026
An illustration featuring a large intestine surrounded by various silhouettes of heads, representing demographics, alongside abstract elements.
Chronic Disease

Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma

September 18, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Next Post
Patient outreach collage: an old desk telephone with a coiled cord, an open brass compass and a blank appointment card

Postdischarge contacts may not significantly affect unplanned healthcare utilization or patient satisfaction

Probiotics collage: a bowl of plain yogurt with a spoon, a jar of kefir, a dill sprig and magnified rod-shaped bacteria

Probiotic use may decrease risk factors for metabolic syndrome

Prenatal Systemic Glucocorticoid Exposure and an Increased Risk of Future Mental Disorders

Prenatal Systemic Glucocorticoid Exposure and an Increased Risk of Future Mental Disorders

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.